|
Session 164
Poster Abstracts
Hepatitis: Treatment Topics
Monday, 1 - 4 pm
Poster Hall |
945
 |
Hepatitis B Virus Plasma Dynamics in HIV/HBV-co-infected Patients: Significant Difference in the Anti-viral Activity of Adefovir and Tenofovir
Karine Lacombe*1,2, Karine Lacombe*1,2, P Y Boelle2, J Gozlan1, G Pialoux3, C Lascoux-Combe4, J M Molina4, P Miailhes5, A Boyd1,2, A Boyd1,2, and P M Girard1
1Hosp St Antoine, Paris, France; 2INSERM U707, Univ Pierre and Marie Curie, Paris, France; 3Hosp Tenon, Paris, France; 4Hosp St Louis, Paris, France; and 5Hotel-Dieu, Lyon, France |
946
|
Pharmacokinetics of Boosted PI and NNRTI in HCV/HIV-co-infected Patients
Dominique Breilh*, S Guinguené, V de Lédinghen, J Toutain, J L Pellegrin, P Trimoulet, I Pellegrin, M Dupon, M C Saux, and D Neau
Ctr Hosp Univ Bordeaux, France |
947
|
Low Rates of HCV Therapy among Treatment-eligible Injection Drug Users with and without HIV Co-infection
M Sulkowski, S Mehta, R Moore, Ruben Montes de Oca*, and D Thomas
Johns Hopkins Univ, Baltimore, MD, US |
948
|
Genetic and Phenotypic Structure of Hepatitis C Virus NS3/4 Protease Quasispecies
S Franco, M Parera, E Aparicio, B Clotet, and Miguel Angel Martinez*
Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Badalona, Spain |
| 949 |
Hepatitis B Virus Kinetics Is Similar in HIV/HBV-co-infected and HBV-mono-infected Individuals
Sharon Lewin*1,2, Sharon Lewin*1,2, R Ribeiro3, A Avihingsanon4,5, A Avihingsanon4,5, S Bowden6, G Matthews7, D Cooper7, S Locarnini6, A Perelson3, K Ruxrungtham4,5, K Ruxrungtham4,5, and G Dore7
1Alfred Hosp, Melbourne, Australia; 2Monash Univ, Melbourne, Australia; 3Los Alamos Natl Lab, NM, US; 4HIV Netherlands Australia Thailand (HIV-NAT) Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 5Chulalongkorn Univ, Bangkok, Thailand; 6Victorian Infectious Diseases Reference Lab, Melbourne, Australia; and 7Natl Ctr for HIV Epidemiology and Clin Res, Sydney, Australia |
|
